東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Preclinical evaluation of antimicrob...

Bueno, Juan.

Linked to FindBook

Google Book

Amazon

博客來

Preclinical evaluation of antimicrobial nanodrugs

Record Type:	Electronic resources : Monograph/item
Title/Author:	Preclinical evaluation of antimicrobial nanodrugs/ by Juan Bueno.
Author:	Bueno, Juan.
Published:	Cham :Springer International Publishing : : 2020.,
Description:	xi, 117 p. :ill., digital ;24 cm.
[NT 15003449]:	Preface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index.
Contained By:	Springer eBooks
Subject:	Anti-infective agents. -
Online resource:	https://doi.org/10.1007/978-3-030-43855-5
ISBN:	9783030438555

Preclinical evaluation of antimicrobial nanodrugs
Bueno, Juan.

Preclinical evaluation of antimicrobial nanodrugs[electronic resource] /by Juan Bueno. - Cham :Springer International Publishing :2020. - xi, 117 p. :ill., digital ;24 cm. - Nanotechnology in the life sciences,2523-8027. - Nanotechnology in the life sciences..

Preface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index.

Translational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time.

ISBN: 9783030438555

Standard No.: 10.1007/978-3-030-43855-5doiSubjects--Topical Terms:

634368
Anti-infective agents.

LC Class. No.: RM267 / .B846 2020

Dewey Class. No.: 615.792

Preclinical evaluation of antimicrobial nanodrugs
LDR:03282nmm a2200337 a 4500 001 2254853
003 DE-He213
005 20200918132522.0
006 m d
007 cr nn 008maaau
008 220419s2020 sz s 0 eng d
020 $a 9783030438555 $q (electronic bk.)
020 $a 9783030438548 $q (paper)
024 7 $a 10.1007/978-3-030-43855-5 $2 doi
035 $a 978-3-030-43855-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM267 $b .B846 2020
072 7 $a MMFM $2 bicssc
072 7 $a MED052000 $2 bisacsh
072 7 $a MKFM $2 thema
082 0 4 $a 615.792 $2 23
090 $a RM267 $b .B928 2020
100 1 $a Bueno, Juan. $3 3524084
245 1 0 $a Preclinical evaluation of antimicrobial nanodrugs $h [electronic resource] / $c by Juan Bueno.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xi, 117 p. : $b ill., digital ; $c 24 cm.
490 1 $a Nanotechnology in the life sciences, $x 2523-8027
505 0 $a Preface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index.
520 $a Translational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time.
650 0 $a Anti-infective agents. $3 634368
650 0 $a Nanomedicine. $3 900993
650 1 4 $a Medical Microbiology. $3 890951
650 2 4 $a Microbial Genetics and Genomics. $3 891163
650 2 4 $a Nanotechnology. $3 526235
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
650 2 4 $a Plant Breeding/Biotechnology. $3 899391
650 2 4 $a Plant Biochemistry. $3 892411
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Nanotechnology in the life sciences. $3 3384316
856 4 0 $u https://doi.org/10.1007/978-3-030-43855-5
950 $a Biomedical and Life Sciences (Springer-11642)